Lupus Australia Briefing

Initial Phase 1b data from Climb Bio on budoprutug in SLE adds to the emerging therapy pipeline, with a subcutaneous formulation under evaluation for this and other autoimmune conditions.

The NHS's experimental treatment has achieved groundbreaking lupus remission in UK trials, offering Australian advocates a compelling case to demand equivalent access and funding at federal and state levels.

The Lupus Foundation Australasia Fundraising Toolkit equips advocates to host events like morning teas or marathons, raising awareness and funds for...

Early UK trials show CAR-T therapy resetting the immune system to achieve remission in lupus, with five of six patients still well after 18 months and...

Neuropsychiatric lupus presents serious diagnostic hurdles, with symptoms like headaches, seizures and cognitive issues often overlapping other...

Early UK data signals real momentum for CAR T-cell therapy in treatment-resistant lupus.

• Autolus obe-cel achieved encouraging clinical benefit with...

Albert T. Roy, president of the Lupus Research Alliance, argues the future of lupus treatment depends heavily on precision medicine. The 'N of One' approach highlights the need for biomarker-driven, individualised strategies.

Early control of systemic lupus erythematosus is advancing, with EULAR 2026 reflections stressing support for scientific and patient communities to enable earlier benefits for those with rheumatological conditions.

Two EULAR 2026 abstracts reveal LLMs' growing role in SLE care.

• Patient education: ChatGPT-5, Claude 4.0 and Gemini 2.5 Pro delivered more accurate,...

TYK2 inhibitors demonstrate clinical relevance for systemic lupus erythematosus (SLE), alongside psoriatic arthritis and Sjögren's syndrome. This emerging class offers a novel therapeutic avenue for autoimmune disease management.

Hydroxychloroquine may improve cutaneous disease control and overall lupus outcomes in atypical lower extremity discoid lupus erythematosus. Early intervention could help prevent progression.

Federal Funding Announcement

• 🔥 PM backs $100m mission: The federal government will invest a record $100m during the next decade into arthritis...

Three converging developments strengthen the case for sustained Australian advocacy and investment:

• A landmark Research Mission targets conditions...

The federal government's record $100m decade-long investment in arthritis research explicitly includes lupus as a key autoimmune focus. This...

• Therapy surge ahead: Nine phase 3 lupus programs set to complete in three years, expanding options past current approvals
• Endpoint shift: Move...

FDA clearance of Imviva's CTA313 opens Phase 1b trials in systemic lupus erythematosus and other autoimmune diseases, with the allogeneic off-the-shelf design positioned to speed treatment availability for eligible patients.

• Phase 3 PHOENYCS GO trial met its primary endpoint, with 50% BICLA response at 48 weeks versus 35% on placebo.
• Glucocorticoid-sparing effect...

The SMILE trial found hydroxychloroquine did not reduce progression from incomplete lupus erythematosus to SLE, though 13% of ILE patients met SLE...